Clinical Indication

Treatment of spasticity associated with Multiple Sclerosis


EM Policy

Date of classification

June 2015

Review date

June 2015


Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.